NCT04973098View on ClinicalTrials.gov

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

PHASE1UnknownINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

June 30, 2023

Conditions
Advanced Hepatocellular Carcinoma
Interventions
BIOLOGICAL

CT0181 Cells

5 dose levels each with or without lymphocyte clearance were tentatively determined.

Trial Locations (1)

100142

RECRUITING

Peking University, Beijing

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Peking University

OTHER